Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial

Minerva Neurosciences secured up to $200M in funding to advance its schizophrenia drug roluperidone. The financing follows FDA approval of its Phase 3 trial plan, aiming to treat negative symptoms unmet by current therapies.